Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AEON Biopharma, Inc.AEON · Entity 7859 | Director · PRESIDENT & CEO | February 17, 2026 | February 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AEON Biopharma, Inc.
Report date February 17, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 3,177,103 |
Reported balance
After 2026-02-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-17 · Grant · Acquired 3,000,000 · Balance 3,177,103 F1: Represents an award of restricted stock units granted on February 17, 2026 (the "Grant Date"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units granted on February 17, 2026 (the "Grant Date"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2026 Filed Feb 20, 2026 01:40 UTC | AEON Biopharma, Inc. AEON · Entity 7859 | GrantClass A Common Stock | 3,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-017726 · tm266901-1_4seq1.xml · nonDerivative · entry 1 Bancroft Robert E. · CIK 0002066370 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,177,103 F1 · security: Represents an award of restricted stock units granted on February 17, 2026 (the "Grant Date"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. F1 · price: Represents an award of restricted stock units granted on February 17, 2026 (the "Grant Date"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:17 UTC | AEON Biopharma, Inc. AEON · Entity 7859 | GrantClass A Common Stock | 177,103 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000120 · form4.xml · nonDerivative · entry 1 Bancroft Robert E. · CIK 0002066370 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,103 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Class A Common Stock for each RSU upon vesting. 25% of the RSUs shall vest on each anniversary of April 29, 2025. Read SEC document |
| April 29, 2025 Filed May 1, 2025 20:50 UTC | AEON Biopharma, Inc. AEON · Entity 7859 | GrantStock Option · Derivative | 59,034 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001610717-25-000111 · form4.xml · derivative · entry 1 Bancroft Robert E. · CIK 0002066370 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,034 Underlying: Class A Common Stock · 59,034 shares Expires 2035-04-29 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on each anniversary measured from April 29, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.